Uncategorized

Newcomer anti-IL-33 makes strides in COPD

Published

1 month ago

on

May 7, 2026

By

Temp User

Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-x

AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Endpoints News3 months ago

Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season

Exit mobile version